Monday, March 3, 2014

Melatonin Agonist May Protect Against Delirium

A new study not only adds to the evidence that low levels of the pineal hormone melatonin are implicated in delirium, but suggests that correcting these low levels might be able to prevent delirium. The study, titled "Preventive Effects of Ramelteon on Delirium," was headed by Kotaro Hatta, M.D., Ph.D., a psychiatrist at Juntendo University in Japan. The results appear in JAMA Psychiatry.

The study by Hatta and his coworkers included 67 older hospitalized patients. Half received a melatonin agonist called ramelteon nightly and half received a placebo. Only three percent of the subjects getting ramelteon developed delirium, whereas 32 percent of placebo subjects did--a significant difference.

"This is an interesting study despite the small size of the sample," Gary Kennedy, M.D., a professor of psychiatry at Albert Einstein College of Medicine and director of the Division of Geriatric Psychiatry at Montefiore Medical Center, said in an interview. "It reinforces the novel theory that melatonin is involved in the genesis of delirium and would explain in part why older adults are more likely to develop delirium. The potential of ramelteon to reduce the risk of delirium is especially appealing because of its low adverse reactions, unlike antipsychotics that are so often used when delirious behavior threatens the patient's well-being."

Ramelteon has been approved by the U.S. Food and Drug Administration to treat insomnia.

More information about diagnosing and treating delirium can be found in American Psychiatric Publishing's new Clinical Manual of Geriatric Psychiatry.

(Image: Volodymyr Baleha/


The content of Psychiatric News does not necessarily reflect the views of APA or the editors. Unless so stated, neither Psychiatric News nor APA guarantees, warrants, or endorses information or advertising in this newspaper. Clinical opinions are not peer reviewed and thus should be independently verified.